A $100 million grant will propel Addition Therapeutics and its platform for designing programmable, circular RNA therapeutics into the clinic. The stealth-mode biotech is developing a suite of RNA-based medicines, with its lead candidate, ATX-001, an investigational therapy for solid tumors, poised to enter Phase 1/2 studies. The non-dilutive capital is earmarked specifically to fund the first-in-human trial for ATX-001 and to scale the company's proprietary manufacturing capabilities for its novel RNA constructs. While the grantor was not disclosed, the substantial award suggests backing from a major biomedical research institution or government initiative focused on next-generation therapeutic modalities. The funding arrives as the RNA therapeutics field expands beyond vaccines and liver-targeted medicines toward more complex engineered constructs for oncology and other diseases.